Tags

Type your tag names separated by a space and hit enter

Influenza and other respiratory viruses: standardizing disease severity in surveillance and clinical trials.
Expert Rev Anti Infect Ther 2017; 15(6):545-568ER

Abstract

INTRODUCTION

Influenza-Like Illness is a leading cause of hospitalization in children. Disease burden due to influenza and other respiratory viral infections is reported on a population level, but clinical scores measuring individual changes in disease severity are urgently needed. Areas covered: We present a composite clinical score allowing individual patient data analyses of disease severity based on systematic literature review and WHO-criteria for uncomplicated and complicated disease. The 22-item ViVI Disease Severity Score showed a normal distribution in a pediatric cohort of 6073 children aged 0-18 years (mean age 3.13; S.D. 3.89; range: 0 to 18.79). Expert commentary: The ViVI Score was correlated with risk of antibiotic use as well as need for hospitalization and intensive care. The ViVI Score was used to track children with influenza, respiratory syncytial virus, human metapneumovirus, human rhinovirus, and adenovirus infections and is fully compliant with regulatory data standards. The ViVI Disease Severity Score mobile application allows physicians to measure disease severity at the point-of care thereby taking clinical trials to the next level.

Authors+Show Affiliations

a Division of Pediatric Infectious Diseases , Vienna Vaccine Safety Initiative , Berlin , Germany. b Department of Pediatrics , Charité University Medical Center , Berlin , Germany. c Division of Epidemiology and Public Health , University of Nottingham , Nottingham , UK.d Department of Mathematics and Computer Science , Freie Universität Berlin , Berlin , Germany.c Division of Epidemiology and Public Health , University of Nottingham , Nottingham , UK.a Division of Pediatric Infectious Diseases , Vienna Vaccine Safety Initiative , Berlin , Germany. b Department of Pediatrics , Charité University Medical Center , Berlin , Germany.b Department of Pediatrics , Charité University Medical Center , Berlin , Germany. e National Reference Centre for Influenza and Other Respiratory Viruses , Robert Koch Institute , Berlin , Germany.a Division of Pediatric Infectious Diseases , Vienna Vaccine Safety Initiative , Berlin , Germany. d Department of Mathematics and Computer Science , Freie Universität Berlin , Berlin , Germany.a Division of Pediatric Infectious Diseases , Vienna Vaccine Safety Initiative , Berlin , Germany. b Department of Pediatrics , Charité University Medical Center , Berlin , Germany.a Division of Pediatric Infectious Diseases , Vienna Vaccine Safety Initiative , Berlin , Germany. b Department of Pediatrics , Charité University Medical Center , Berlin , Germany.a Division of Pediatric Infectious Diseases , Vienna Vaccine Safety Initiative , Berlin , Germany. b Department of Pediatrics , Charité University Medical Center , Berlin , Germany.f Clinical Data Standards Interchange Consortium (CDISC) , Austin , TX , USA.e National Reference Centre for Influenza and Other Respiratory Viruses , Robert Koch Institute , Berlin , Germany.

Pub Type(s)

Journal Article
Review
Systematic Review

Language

eng

PubMed ID

28277820

Citation

Rath, Barbara, et al. "Influenza and Other Respiratory Viruses: Standardizing Disease Severity in Surveillance and Clinical Trials." Expert Review of Anti-infective Therapy, vol. 15, no. 6, 2017, pp. 545-568.
Rath B, Conrad T, Myles P, et al. Influenza and other respiratory viruses: standardizing disease severity in surveillance and clinical trials. Expert Rev Anti Infect Ther. 2017;15(6):545-568.
Rath, B., Conrad, T., Myles, P., Alchikh, M., Ma, X., Hoppe, C., ... Schweiger, B. (2017). Influenza and other respiratory viruses: standardizing disease severity in surveillance and clinical trials. Expert Review of Anti-infective Therapy, 15(6), pp. 545-568. doi:10.1080/14787210.2017.1295847.
Rath B, et al. Influenza and Other Respiratory Viruses: Standardizing Disease Severity in Surveillance and Clinical Trials. Expert Rev Anti Infect Ther. 2017;15(6):545-568. PubMed PMID: 28277820.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Influenza and other respiratory viruses: standardizing disease severity in surveillance and clinical trials. AU - Rath,Barbara, AU - Conrad,Tim, AU - Myles,Puja, AU - Alchikh,Maren, AU - Ma,Xiaolin, AU - Hoppe,Christian, AU - Tief,Franziska, AU - Chen,Xi, AU - Obermeier,Patrick, AU - Kisler,Bron, AU - Schweiger,Brunhilde, Y1 - 2017/05/12/ PY - 2017/3/10/pubmed PY - 2018/3/1/medline PY - 2017/3/10/entrez KW - Disease severity KW - adenovirus KW - antivirals KW - clinical trials KW - human metapneumovirus KW - human rhinovirus KW - influenza KW - influenza-like illness KW - respiratory syncytial virus KW - seasonality SP - 545 EP - 568 JF - Expert review of anti-infective therapy JO - Expert Rev Anti Infect Ther VL - 15 IS - 6 N2 - INTRODUCTION: Influenza-Like Illness is a leading cause of hospitalization in children. Disease burden due to influenza and other respiratory viral infections is reported on a population level, but clinical scores measuring individual changes in disease severity are urgently needed. Areas covered: We present a composite clinical score allowing individual patient data analyses of disease severity based on systematic literature review and WHO-criteria for uncomplicated and complicated disease. The 22-item ViVI Disease Severity Score showed a normal distribution in a pediatric cohort of 6073 children aged 0-18 years (mean age 3.13; S.D. 3.89; range: 0 to 18.79). Expert commentary: The ViVI Score was correlated with risk of antibiotic use as well as need for hospitalization and intensive care. The ViVI Score was used to track children with influenza, respiratory syncytial virus, human metapneumovirus, human rhinovirus, and adenovirus infections and is fully compliant with regulatory data standards. The ViVI Disease Severity Score mobile application allows physicians to measure disease severity at the point-of care thereby taking clinical trials to the next level. SN - 1744-8336 UR - https://www.unboundmedicine.com/medline/citation/28277820/Influenza_and_other_respiratory_viruses:_standardizing_disease_severity_in_surveillance_and_clinical_trials_ L2 - http://www.tandfonline.com/doi/full/10.1080/14787210.2017.1295847 DB - PRIME DP - Unbound Medicine ER -